Conclusion Although there were differences in demographics and treatment patterns, advanced-stage EOC had poor prognosis and relatively short progression-free intervals across Asia-Pacific countries with well developed healthcare systems, highlighting the need to develop novel approaches to improve patient outcomes. Variation in the germline BRCA1/2 mutations rates across three datasets is probably due to differences in the composition of the contributing registries (clinic or cohort-based).

Disclosures Anna DeFazio has received a research grant from AstraZeneca.

David Bowtell has received research grants from AstraZeneca, BeiGene and Genentech Roche. David Bowtell is also a consultant for Exo Therapeutics.

Sian Fereday has received a research grant from Genentech Roche.

Nadia Traficante has received a research grant from AstraZeneca.

Oncology Department 1GRO-Kruszynki Institute of Oncology (Ico)-Girona, Girona Biomedical Research Institute (Idibgi); Medical Oncology Department, 3Laboratory Diagnostics Centre, Polish Mother’s Memorial Hospital – Research Institute, 4Institute of Medical Biology, Polish Academy of Sciences.

Disclosures All authors report no conflict of interest.

REAL-WORLD-DATA ON PLATINUM OUTCOMES AFTER PARP INHIBITORS PROGRESSION IN HIGH GRADE SEROUS OVARIAN CANCER PATIENTS

1Andrea Plaja Salarich, 2Iris Teruel García, 3Beatriz Pardo Burdalo, 4Martina Piulats Rodriguez, 5Cecilia Fina Planas, 6Maria Pilar Barretrina Ginesta, 7Andrea Gonzalez Valenca, 8Anna Esteve Gomez, 9Margarita Romero Marin. 1Catalan Institute of Oncology (Ico)-Badalona, Germans Trias i Pujol University Hospital (Hutgip); Badalona-Applied Research Group in Oncology (B-Argo); Medical Oncology Department; 2Catalan Institute of Oncology (Ico)-Idiàbel, L’hostapiet; Medical Oncology Department; 3Catalan Institute of Oncology (Ico)-Girona, Girona Biomedical Research Institute (idibgi); Medical Oncology Department; 4Catalan Institute of Oncology (Ico)-Badalona, Germans Trias i Pujol University Hospital (Hutgip); Badalona-Applied Research Group in Oncology (B-Argo); Statistics Department.